Kiora Pharmaceuticals, Inc.
KPRX
$2.84
$0.1917.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 16.00M | 16.00M | 16.00M |
| Total Other Revenue | 0.00 | 20.00K | 20.00K | 20.00K | 20.00K |
| Total Revenue | 0.00 | 20.00K | 16.02M | 16.02M | 16.02M |
| Cost of Revenue | 607.10K | 605.10K | -242.60K | 589.60K | 357.40K |
| Gross Profit | -607.10K | -585.10K | 16.26M | 15.43M | 15.66M |
| SG&A Expenses | 5.55M | 5.74M | 5.54M | 5.10M | 5.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.52M | 9.70M | 10.44M | 9.93M | 9.73M |
| Operating Income | -9.52M | -9.68M | 5.58M | 6.09M | 6.29M |
| Income Before Tax | -9.91M | -9.86M | 5.66M | 5.64M | 3.29M |
| Income Tax Expenses | 2.08M | 2.19M | 2.07M | 90.30K | 90.30K |
| Earnings from Continuing Operations | -11.98 | -12.05 | 3.59 | 5.55 | 3.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.98M | -12.05M | 3.59M | 5.55M | 3.20M |
| EBIT | -9.52M | -9.68M | 5.58M | 6.09M | 6.29M |
| EBITDA | -9.51M | -9.67M | 5.60M | 6.12M | 6.32M |
| EPS Basic | -2.87 | -2.86 | 2.32 | 0.61 | -6.55 |
| Normalized Basic EPS | -1.27 | -1.25 | 1.93 | 0.72 | -0.77 |
| EPS Diluted | -2.87 | -2.86 | 1.12 | -0.60 | -7.76 |
| Normalized Diluted EPS | -1.27 | -1.25 | 1.18 | -0.04 | -1.53 |
| Average Basic Shares Outstanding | 16.64M | 16.82M | 15.49M | 12.10M | 8.68M |
| Average Diluted Shares Outstanding | 16.64M | 16.82M | 16.50M | 13.11M | 9.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |